Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
  • English
    • 日本語
Evaluate Logo

navigation

  • What We Do
  • Vantage
    • News
    • Analysis
    • Policy & Pricing
    • Data Insights
    • Events
    • Medtech
    • Therapy Areas
    • About Vantage
      • Editorial team
  • Products & Services
    • Consensus Forecasts
    • Pharma
      • EvaluatePharma
      • EvaluatePharma Vision
    • Custom Solutions
    • How We Can Help You
      • Pharma and Biotech
      • Medtech
      • Financial Services
      • Management Consultancies
      • Service Providers
    • Client Success
    • Customer Testimonials
  • Thought Leadership
    • English
    • 日本語
  • About Us
    • Media Centre
      • Press Releases
      • Media Coverage
    • Executive Team
    • Vision & History
  • Careers
    • Current Vacancies
  • Contact Us
  • Sign Up for Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Policy & Pricing
    • Policy & Regulation
    • Pricing
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Priority Review

Thumbnail
November 16, 2018

Upcoming events – Vertex awaits triplet data and GBT seeks approval for approval

Vertex is due the first pivotal data on its cystic fibrosis triplets, while Global Blood Therapeutics will soon find out whether it can take a shortcut on voxelotor’s path to market.

Thumbnail
August 01, 2018

Pharma’s fastest followers revealed

Analysis of me-too drug approvals over time shows trends across therapy areas.

Article image
Vantage logo
July 27, 2018

Upcoming events – FDA decisions loom for Alnylam and Pfizer

The companies hope that the US regulator approves patisiran and lorlatinib.

Article image
Vantage logo
July 17, 2018

Roche tries again with a new pill for flu

A new influenza antiviral from Roche and Shionogi could become an important new medicine for both groups, if payers can be convinced.

Vantage logo
June 27, 2018

Global Blood launches bold bid for early sickle cell approval

Vantage logo
May 25, 2018

To avoid disappointment bet on cancer and musculoskeletals

Vantage logo
February 12, 2018

Interview – Alnylam needs to get the price right for patisiran

Vantage logo
February 05, 2018

Asco-GU – J&J’s Zytiga follow-on strategy crumbles on Spartan

Article image
Vantage logo
January 16, 2018

Blockbuster approvals line up for biopharma in 2018

2018 shaping up to be a bumper approval year, as Juno Therapeutics, Epizyme and Avexis line up to launch potential blockbusters.

Vantage logo
November 09, 2017

Sage up on the downs

Article image
Vantage logo
November 03, 2017

Astra wins a speedy nod as US novel drug approvals swell

FDA back in business after 2016's fall in drug approvals.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 31, 2019

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

February 26, 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

View more...

Editor's Picks

Vantage logo
October 22, 2019

Shock revelation sees Biogen erase its aducanumab losses

Vantage logo
October 22, 2019

Vertex’s double cystic fibrosis surprise

Vantage logo
October 23, 2019

Bristol might play a role in front-line lung cancer after all

Vantage logo
October 23, 2019

Bloated on arrival? Biotech's weightiest new issues

Vantage logo
October 14, 2019

Uncovering biopharma’s hidden treasures

Open modal

Evaluate HQ +44-(0)20-7377-0800

Evaluate Americas +1-617-573-9450

Evaluate APAC +81 (0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

Follow Us

© Copyright 2019 Evaluate Ltd.